{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:51:11Z","timestamp":1781067071014,"version":"3.54.1"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T00:00:00Z","timestamp":1641945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013365","name":"West China Hospital, Sichuan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004829","name":"Department of Science and Technology of Sichuan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p>CD30-directed chimeric antigen receptors (CARs) with single chain antibody fragment (scFv)-binding domains from murine HRS3 show strong cytotoxicity to Hodgkin\u2019s Lymphoma cells and have been used in clinical trials. However, murine scFv in CAR might induce specific rejective immune responses in patients, which compromises the therapeutic effects. The use of human or humanized antibody fragments for CAR construction, rather than those derived from mouse antibodies, can reduce the immunogenicity of the CAR. Importantly, this strategy might simultaneously decrease the risk of cytokine-mediated toxicities and improve CAR T cell persistence. Murine HRS3 antibody has been successfully humanized by grafting the complementarity-determining regions (CDRs) from the mouse antibody framework onto human immunoglobulin consensus sequences, followed by an <jats:italic>in vitro<\/jats:italic> evolutionary strategy to select functional Fab fragments with the same affinity as murine sources. In this study, humanized scFvs were utilized to construct a CD30-directed CAR (hHRS3-CAR), and its effectiveness was compared with that of HRS3-CAR. The hHRS3-CAR-T cells specifically kill CD30-positive tumor cell lines <jats:italic>in vitro<\/jats:italic> and eliminate lymphoma xenografts in immunodeficient mice with comparable efficiency to HRS3-CAR. The hHRS-CAR-T could be used in clinical trials based on the previously reported advantages of humanized CARs, such as the reduction of immune rejection and better persistence of cells.<\/jats:p>","DOI":"10.3389\/fcell.2021.775599","type":"journal-article","created":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T07:03:52Z","timestamp":1641971032000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Humanized CD30-Targeted Chimeric Antigen Receptor T Cells Exhibit Potent Preclinical Activity Against Hodgkin\u2019s Lymphoma Cells"],"prefix":"10.3389","volume":"9","author":[{"given":"Jing","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjie","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s40425-016-0188-z","article-title":"The Society for Immunotherapy of Cancer Consensus Statement on Immunotherapy for the Treatment of Hematologic Malignancies: Multiple Myeloma, Lymphoma, and Acute Leukemia","volume":"4","author":"Boyiadzis","year":"2016","journal-title":"J. Immunotherapy Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s12967-015-0519-8","article-title":"Identification and Selective Expansion of Functionally superior T Cells Expressing Chimeric Antigen Receptors","volume":"13","author":"Chang","year":"2015","journal-title":"J. Transl Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1093\/annonc\/3.suppl_4.s53","article-title":"Immunoscintigraphy in Hodgkin's Disease and Anaphastic Large Cell Lymphomas: Results in 18 Patients Using the Iodine Radiolabeled Monoclonal Antibody HRS-3","volume":"3","author":"da Costa","year":"1992","journal-title":"Ann. Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"6392","DOI":"10.1182\/blood-2009-03-209650","article-title":"T Lymphocytes Coexpressing CCR4 and a Chimeric Antigen Receptor Targeting CD30 Have Improved Homing and Antitumor Activity in a Hodgkin Tumor Model","volume":"113","author":"Di Stasi","year":"2009","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific Activation and Targeting of Cytotoxic Lymphocytes through Chimeric Single Chains Consisting of Antibody-Binding Domains and the Gamma or Zeta Subunits of the Immunoglobulin and T-Cell Receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1182\/bloodadvances.2017011346","article-title":"A Primary Role for Human central Memory Cells in Tissue Immunosurveillance","volume":"2","author":"Gehad","year":"2018","journal-title":"Blood Adv."},{"key":"B7","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12885-019-5415-9","article-title":"Challenges of Driving CD30-Directed CAR-T Cells to the Clinic","volume":"19","author":"Grover","year":"2019","journal-title":"BMC Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"101304","DOI":"10.1016\/j.beha.2021.101304","article-title":"Advances in CAR Design","volume":"34","author":"Heard","year":"2021","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"B9","first-page":"1116","article-title":"An Anti-CD30 Chimeric Receptor that Mediates CD3-zeta-independent T-Cell Activation against Hodgkin's Lymphoma Cells in the Presence of Soluble CD30","volume":"58","author":"Hombach","year":"1998","journal-title":"Cancer Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.ymthe.2019.06.007","article-title":"Blocking CD30 on T Cells by a Dual Specific CAR for CD30 and Colon Cancer Antigens Improves the CAR T Cell Response against CD30\u2212 Tumors","volume":"27","author":"Hombach","year":"2019","journal-title":"Mol. Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1038\/gt.2010.91","article-title":"Adoptive Immunotherapy with Genetically Engineered T Cells: Modification of the IgG1 Fc 'spacer' Domain in the Extracellular Moiety of Chimeric Antigen Receptors Avoids 'off-Target' Activation and Unintended Initiation of an Innate Immune Response","volume":"17","author":"Hombach","year":"2010","journal-title":"Gene Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1002\/ijc.2910550523","article-title":"A CD16\/CD30 Bispecific Monoclonal Antibody Induces Lysis of Hodgkin's Cells by Unstimulated Natural Killer cellsIn ANDIn Vivo","volume":"55","author":"Hombach","year":"1993","journal-title":"Int. J. Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1158\/2326-6066.CIR-18-0065","article-title":"CD30-Redirected Chimeric Antigen Receptor T Cells Target CD30+ and CD30\u2212 Embryonal Carcinoma via Antigen-dependent and Fas\/FasL Interactions","volume":"6","author":"Hong","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e44482","DOI":"10.1371\/journal.pone.0044482","article-title":"An IL12-IL2-antibody Fusion Protein Targeting Hodgkin's Lymphoma Cells Potentiates Activation of NK and T Cells for an Anti-tumor Attack","volume":"7","author":"Jahn","year":"2012","journal-title":"PLoS One"},{"key":"B15","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/mt.2014.208","article-title":"Chimeric Antigen Receptors with Mutated IgG4 Fc Spacer Avoid Fc Receptor Binding and Improve T Cell Persistence and Antitumor Efficacy","volume":"23","author":"Jonnalagadda","year":"2015","journal-title":"Mol. Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell Depletion and Remissions of Malignancy along with Cytokine-Associated Toxicity in a Clinical Trial of Anti-CD19 Chimeric-Antigen-Receptor-Transduced T Cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1200\/JCO.2006.05.9964","article-title":"Treatment of Metastatic Renal Cell Carcinoma with Autologous T-Lymphocytes Genetically Retargeted against Carbonic Anhydrase IX: First Clinical Experience","volume":"24","author":"Lamers","year":"2006","journal-title":"Jco"},{"key":"B18","doi-asserted-by":"publisher","first-page":"987","DOI":"10.3324\/haematol.2019.231183","article-title":"CD28.OX40 Co-stimulatory Combination Is Associated with Long In Vivo Persistence and High Activity of CAR.CD30 T-Cells","volume":"106","author":"Marika Guercio","year":"2021","journal-title":"haematol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12967-020-02218-x","article-title":"Immunological Effects of Adjuvants in Subsets of Antigen Presenting Cells of Cancer Patients Undergoing Chemotherapy","volume":"18","author":"Mauriello","year":"2020","journal-title":"J. Transl Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study","volume":"30","author":"Pro","year":"2012","journal-title":"Jco"},{"key":"B21","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering Strategies to Overcome the Current Roadblocks in CAR T Cell Therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1172\/JCI94306","article-title":"Clinical and Immunological Responses after CD30-specific Chimeric Antigen Receptor-Redirected Lymphocytes","volume":"127","author":"Ramos","year":"2017","journal-title":"J. Clin. Invest."},{"key":"B23","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"Jco"},{"key":"B24","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s002620050617","article-title":"Initiation of Humoral and Cellular Immune Responses in Patients with Refractory Hodgkin's Disease by Treatment with an Anti-cd16\/cd30 Bispecific Antibody","volume":"49","author":"Renner","year":"2000","journal-title":"Cancer Immunol. Immunother."},{"key":"B25","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The Basic Principles of Chimeric Antigen Receptor Design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov."},{"key":"B26","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40259-013-0068-8","article-title":"CD30 as a Therapeutic Target for Lymphoma","volume":"28","author":"Schirrmann","year":"2014","journal-title":"BioDrugs"},{"key":"B27","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1093\/protein\/gzh098","article-title":"Functional Humanization of an Anti-CD30 Fab Fragment for the Immunotherapy of Hodgkin's Lymphoma Using an In Vitro Evolution Approach","volume":"17","author":"Schlapschy","year":"2004","journal-title":"Protein Eng. Des. Selection"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1182\/blood.v74.5.1678.1678","article-title":"BER-H2: a New Anti-ki-1 (CD30) Monoclonal Antibody Directed at a Formol- Resistant Epitope","volume":"74","author":"Schwarting","year":"1989","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1038\/leu.2017.57","article-title":"Fully Human CD19-specific Chimeric Antigen Receptors for T-Cell Therapy","volume":"31","author":"Sommermeyer","year":"2017","journal-title":"Leukemia"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1158\/2326-6066.CIR-19-0026","article-title":"Eradication of Hepatocellular Carcinoma by NKG2D-Based CAR-T Cells","volume":"7","author":"Sun","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.3390\/cancers12092612","article-title":"CD19-CAR-T Cells Bearing a KIR\/PD-1-Based Inhibitory CAR Eradicate CD19+HLA-C1\u2212 Malignant B Cells while Sparing CD19+HLA-C1+ Healthy B Cells","volume":"12","author":"Tao","year":"2020","journal-title":"Cancers"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T Cells of Defined CD4+:CD8+ Composition in Adult B Cell ALL Patients","volume":"126","author":"Turtle","year":"","journal-title":"J. Clin. Invest."},{"key":"B33","doi-asserted-by":"publisher","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of Non-hodgkin's Lymphoma with a Defined Ratio of CD8 + and CD4 + CD19-specific Chimeric Antigen Receptor-Modified T Cells","volume":"8","author":"Turtle","year":"","journal-title":"Sci. Transl. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e603","DOI":"10.1038\/bcj.2017.85","article-title":"Understanding CD30 Biology and Therapeutic Targeting: a Historical Perspective Providing Insight into Future Directions","volume":"7","author":"van der Weyden","year":"2017","journal-title":"Blood Cancer J."},{"key":"B35","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41571-021-00476-2","article-title":"Immunogenicity of CAR T Cells in Cancer Therapy","volume":"18","author":"Wagner","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1158\/1078-0432.CCR-16-1365","article-title":"Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial","volume":"23","author":"Wang","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41408-020-0274-9","article-title":"Anti-CD30 Chimeric Antigen Receptor T Cell Therapy for Relapsed\/refractory CD30+ Lymphoma Patients","volume":"10","author":"Wang","year":"2020","journal-title":"Blood Cancer J."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1901829","DOI":"10.1002\/advs.201901829","article-title":"Dynamic Profiling of Antitumor Activity of CAR T Cells Using Micropatterned Tumor Arrays","volume":"6","author":"Wang","year":"2019","journal-title":"Adv. Sci."},{"key":"B39","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1159\/000347192","article-title":"Targeting CD30 in Malignant Tissues: Challenges in Detection and Clinical Applications","volume":"80","author":"Wasik","year":"2013","journal-title":"Pathobiology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.7150\/thno.24401","article-title":"HUWE1 Controls the Development of Non-small Cell Lung Cancer through Down-Regulation of P53","volume":"8","author":"Yang","year":"2018","journal-title":"Theranostics"},{"key":"B41","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s40425-019-0642-9","article-title":"T Cells Expressing NKG2D Chimeric Antigen Receptors Efficiently Eliminate Glioblastoma and Cancer Stem Cells","volume":"7","author":"Yang","year":"2019","journal-title":"J. Immunotherapy Cancer"},{"key":"B42","doi-asserted-by":"publisher","first-page":"4773","DOI":"10.1158\/0008-5472.CAN-16-2597","article-title":"Huwe1 Sustains Normal Ovarian Epithelial Cell Transformation and Tumor Growth through the Histone H1.3-H19 Cascade","volume":"77","author":"Yang","year":"2017","journal-title":"Cancer Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin's Lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"Jco"},{"key":"B44","doi-asserted-by":"publisher","first-page":"5595","DOI":"10.1158\/1078-0432.CCR-19-0916","article-title":"Treatment with Humanized Selective CD19CAR-T Cells Shows Efficacy in Highly Treated B-ALL Patients Who Have Relapsed after Receiving Murine-Based CD19CAR-T Therapies","volume":"25","author":"Zhao","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"B45","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13045-018-0676-3","article-title":"Chimeric Antigen Receptor-Modified T Cell Therapy in Chronic Lymphocytic Leukemia","volume":"11","author":"Zou","year":"2018","journal-title":"J. Hematol. Oncol."}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2021.775599\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T07:03:55Z","timestamp":1641971035000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2021.775599\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,12]]},"references-count":45,"alternative-id":["10.3389\/fcell.2021.775599"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2021.775599","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,12]]},"article-number":"775599"}}